Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET

Company Participants

Holly Manning - Senior Director, Investor Relations

Jackie Fouse - Chief Executive Officer

Sarah Gheuens - Chief Medical Officer and Head of R&D

Richa Poddar - Chief Commercial Officer

Jonathan Biller - Chief Financial Officer and Head of Corporate Affairs

Conference Call Participants

Marc Frahm - Cowen

Andrew Berens - SVB Leerink

Danielle Brill - Raymond James

Operator

Good morning and welcome to Agios Second Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end of the call. Please be advised that this call is being recorded at Agios' request.

I would now like to turn the conference over to Holly Manning, Senior Director of Investor Relations. Please go ahead.

Holly Manning

Thank you, operator. Good morning, everyone, and welcome to Agios' second quarter 2022 conference call. You can access slides for today's call by going to the Investors Section of our website, agios.com.

With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Sarah Gheuens, our Chief Medical Officer and Head of Research and Development; Richard Poddar, our Chief Commercial Officer; and Jonathan Biller, our Chief Financial Officer and Head of Corporate Affairs.

Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC.

With that, I will turn the call over to Jackie.

Jackie Fouse

Thanks Holly. Good morning, everyone and thanks for joining our second quarter 2022 results call. The first half of 2022 has been remarkably productive across all facets of our business. I've continued to be impressed by the focused execution of the Agios team and their connection to each other and our vision of making an impact on the lives of patients.

In February, our world-class commercial organization launched our first genetically defined disease medicine, PYRUKYND, which is the first FDA approved therapy to treat pyruvate kinase deficiency and the first ever approved PK activator. Today, we report impressive commercial performance for our first full quarter of launch, which Richard will cover in more detail.